GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » Interest Coverage

Mereo BioPharma Group (LTS:0A9G) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Mereo BioPharma Group's Operating Income for the three months ended in Dec. 2024 was $-14.70 Mil. Mereo BioPharma Group's Interest Expense for the three months ended in Dec. 2024 was $-0.38 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Mereo BioPharma Group's Interest Coverage or its related term are showing as below:


LTS:0A9G's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 101.38
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Mereo BioPharma Group Interest Coverage Historical Data

The historical data trend for Mereo BioPharma Group's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mereo BioPharma Group Interest Coverage Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mereo BioPharma Group Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mereo BioPharma Group's Interest Coverage

For the Biotechnology subindustry, Mereo BioPharma Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Interest Coverage falls into.


;
;

Mereo BioPharma Group Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mereo BioPharma Group's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Mereo BioPharma Group's Interest Expense was $-1.37 Mil. Its Operating Income was $-45.72 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.19 Mil.

Mereo BioPharma Group did not have earnings to cover the interest expense.

Mereo BioPharma Group's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, Mereo BioPharma Group's Interest Expense was $-0.38 Mil. Its Operating Income was $-14.70 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.19 Mil.

Mereo BioPharma Group did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Mereo BioPharma Group  (LTS:0A9G) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Mereo BioPharma Group Interest Coverage Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines